# Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression

> **NCT03724968** · PHASE2 · TERMINATED · sponsor: **Elizabeth Davis** · enrollment: 2 (actual)

## Conditions studied

- Metastatic Melanoma
- Advanced Melanoma
- Metastatic Melanoma Stratified by MHC-II Expression

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Relatlimab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03724968
- **Lead sponsor:** Elizabeth Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-17
- **Primary completion:** 2020-05-28
- **Final completion:** 2020-05-28
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Loss of funding
- **Last updated:** 2021-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03724968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03724968, "Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03724968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*